PolyPeptide Group AG reported preliminary 2025 results showing revenue of about EUR 389 million, an implied increase of roughly 15.6% over 2024. EBITDA margin reached 11 to 12%, up from 7.5%. The company reaffirmed plans to double 2023 revenue by 2028.
On
, PolyPeptide Group AG SIX: PPGN announced that its financial year 2025 closed with strong revenue growth and a marked improvement in profitability. The company is a contract development and manufacturing organization, or CDMO, that specializes in peptide-based active pharmaceutical ingredients. Peptides are short chains of amino acids that serve as the active components in many modern medicines. The figures released are preliminary and unaudited. PolyPeptide made the announcement as an ad hoc disclosure under Article 53 of the Listing Rules from its base in Baar, Switzerland. The results are consistent with the revised guidance the company issued at the time of its first-half 2025 results.
PolyPeptide generated revenue of approximately EUR 389 million in 2025. That represents an implied growth rate of about 15.6% compared with the prior year, mainly driven by metabolic therapeutics. When currency movements are removed and results are measured at constant currency rates, growth was slightly higher and came in around the midpoint of the company’s guidance. The metabolic therapeutics category includes drugs related to conditions such as diabetes and obesity, including the expanding GLP-1 market. GLP-1 is a naturally occurring hormone that helps regulate blood sugar and appetite, and pharmaceutical versions have seen rapidly accelerating demand.
Capacity expansion also progressed during the year. A large-scale solid-phase peptide synthesis, or SPPS, asset in Braine-l’Alleud, Belgium, achieved its target utilization rate. SPPS is a manufacturing method in which amino acids are added step by step to a growing peptide chain attached to a solid support. It is widely used to produce peptide drugs at commercial scale. Reaching target utilization at that facility is an important sign that PolyPeptide’s expanded production capacity is being put to use.
Profitability improved sharply in the 2025 financial year. EBITDA margin reached between 11% and 12%, toward the upper end of guidance and up from 7.5% in 2024. EBITDA stands for earnings before interest, taxes, depreciation, and amortization, and it is a common measure of operating profitability. Capital expenditures were just over EUR 100 million, in line with the company’s guidance, reflecting continued investment in production capacity.
Operating cash flow improved during the year, and PolyPeptide also increased its financing flexibility through an expansion of its existing credit facility announced in May 2025. At year end, the company held cash and cash equivalents of EUR 75 million. In addition, EUR 51 million remained undrawn and available under the EUR 151 million committed revolving credit facility. A revolving credit facility is a type of loan that allows a company to draw funds up to a set limit, repay them, and borrow again as needed.
Juan José Gonzalez, CEO of PolyPeptide, said: “The strong momentum we achieved in 2025 reflects improved execution across our multi-site network, a rich development pipeline, and rapid growth in the expanding GLP-1 market. As demand continues to accelerate, PolyPeptide is well positioned, leveraging its peptide expertise and proprietary technologies, to deliver on its mid-term targets. We will continue to strengthen our capabilities, expand capacity in close partnership with customers, and maintain the financial flexibility required to support long-term growth.”
.
A number of later announcements are listed alongside the
, release. On
, Samsung Biologics announced a tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share. On
, PolyPeptide Group AG said it had taken note of market rumors and speculation. On
, PolyPeptide reported strong revenue growth and a marked improvement in profitability, reflecting the same trend described in the preliminary full-year figures.
Peptides referenced: GLP-1.
Related reading: Reducing Benzotriazole and Solvent Hazards in Peptide Synthesis, Peptide Chirality as a Tuning Lever for Polyelectrolyte Complexes, Peptide Purification Bottlenecks and PEC 2.0 Solutions, CordenPharma to Acquire AmbioPharm, Expanding Peptide API Capacity.